Glaukos (GKOS)
(Delayed Data from NYSE)
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$130.98 USD
+4.18 (3.30%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $130.94 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
STERIS (STE) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) Key Surgical and Cantel Medical businesses make significant contributions to consumable revenues within the Healthcare arm in Q1.
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.
Intuitive Surgical (ISRG) Q2 Earnings Miss, Procedures Recover
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect health demand for procedures despite the resurgence of COVID-19 infections.
Here's Why Glaukos (GKOS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Glaukos (GKOS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is a Beat Likely for Intuitive Surgical (ISRG) in Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Best Momentum Stocks to Buy for July 13th
by Zacks Equity Research
JAZZ, GKOS and SPPI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 13, 2022.
Here's Why You Should Add Glaukos (GKOS) to Your Portfolio
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Has Glaukos (GKOS) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Glaukos (GKOS) and Alkermes (ALKS) have performed compared to their sector so far this year.
New Strong Buy Stocks for July 13th
by Zacks Equity Research
KMI, UFCS, GKOS, SPPI and BECN have been added to the Zacks Rank #1 (Strong Buy) List on July 13, 2022.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Glaukos (GKOS) Stock Falls 25.9% Despite Q1 Earnings Beat
by Zacks Equity Research
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Despite reporting a fourth-quarter loss, Glaukos' (GKOS) results reflect a noticeable rise in revenues.
Glaukos (GKOS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 16.22% and 8.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Glaukos (GKOS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and solid performing iStent technology.
Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3
by Zacks Equity Research
Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.
Glaukos (GKOS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Glaukos (GKOS) delivered earnings and revenue surprises of 17.39% and 3.73%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Glaukos (GKOS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Glaukos (GKOS) Stock Now
by Zacks Equity Research
Glaukos Corporation (GKOS) continues to benefit from robust product portfolio and solid performing iStent technology.